LDS/Medical Tests/GSTP1, APC, RASSF1 Promoter Methylation Profiling (ConfirmMDx) for Prostate Cancer

GSTP1, APC, RASSF1 Promoter Methylation Profiling (ConfirmMDx) for Prostate Cancer

ConfirmMDx assesses the methylation status of 3 biomarkers (GSTP1, RASSF1, APC) associated with prostate cancer. ConfirmMDx is intended for use in patients with high-risk factors such as elevated/rising prostate-specific antigen (PSA) or abnormal digital rectal examination (DRE), with a negative or non-malignant abnormal histopathology finding (e.g., atypical cell or high grade prostate intraepithelial neoplasia (HGPIN)) in the previous biopsy, and is being considered for repeat biopsy. Independently published clinical studies have shown that for men who have received a negative prostate biopsy result, ConfirmMDx is the single most significant predictor of patient outcome among all currently available clinical factors, such as age, PSA level, and DRE results.

GSTP1 is the most intensely studied and widely reported epigenetic biomarker associated with prostate cancer diagnosis, encoding the glutathione S-transferase Pi 1 protein involved in detoxification, due to its high sensitivity and specificity. Complementing GSTP1, methylation of the APC and RASSF1 genes is frequently found in prostate cancer, and these markers have demonstrated a “field effect” aiding in the identification of biopsies with false-negative histopathological results.

The performance of this assay in a large, blinded clinical validation study demonstrated a NPV of 90% for all prostate cancer and 96% for high-grade disease, which is considerably higher than that afforded by standard histopathology review.

  • Detection of occult prostate cancer on a patient’s previously biopsied negative tissue to aid in diagnosis and management of prostate cancer
Positive ConfirmMDx DNA methylation indicates an 41%-60% likelihood of detecting prostate cancer, with a 22% probability for low-grade disease (GS ≤ 6) versus a 19% probability of high-grade disease (GS ≥ 7), on repeat biopsy.

ConfirmMDx DNA methylation Negative

Bisulfite conversion of methylated DNA, followed by Real-time PCR amplification with allele specific primers, Methylation-specific pyrosequencing, combined bisulfite restriction analysis (COBRA) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA).

Formalin-fixed, paraffin-embedded tissue blocks, or slides.

Prostate biopsy, PSA.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login